China International Capital Corporation: Peptide production ushers in the opportunities of the times with the rapid expansion of GLP-1.
In terms of the global pattern, Swiss companies are leading in peptide production, while China is the main supplier of GLP-1 active pharmaceutical ingredients.
China NT Pharma Group Looks to Enter Orthopedics Sector
Shanghai supports the use of AI technology in drug research and development, and continues to increase its support for the development of innovative drugs.
On July 30, the Shanghai Municipal People's Government Office issued several opinions on supporting the innovative development of the entire biomedical industry chain.
Hong Kong stock concept tracking | Diabetes prevention and control action plan released, significant progress has been made in the innovative drug research and development of these enterprises (with concept stocks).
According to Frost & Sullivan data, the scale of China's diabetes medication market is expected to reach 167.5 billion yuan by 2030.
NT Pharma (01011.HK) plans to collaborate with Shanxi Ningle Pharmaceutical Logistics to develop cooperation in the field of orthopedic products and related services.
On July 29th, Gelonhui announced that in order to further strengthen the cooperation between the company and Shanxi Ningle Medical Logistics Co., Ltd., on July 29th, 2024, the company and Shanxi Ningle Medical Logistics Co., Ltd. entered into a non-binding memorandum of understanding for possible cooperation. According to the memorandum of understanding, the company and Shanxi Ningle Medical Logistics Co., Ltd. plan to cooperate on the possibility of the group's products and related service projects in the field of orthopedics, and the possibility of cooperation in suitable orthopedic products and their related peripheral services. Shanxi Ningle Medical Logistics Co., Ltd. will provide the greatest possible support.
Express News | China NT Pharma Group - Mou for Possible Cooperation on Group's Products and Related Service Projects in Field of Orthopedics
Express News | China NT Pharma Group - Co and Shanxi Ningle Pharmaceutical Logistics Entered Non-Legally Binding Memorandum of Understanding
China NT Pharma Terminates License Agreement With Abcentra for Monoclonal Antibody Technology; Shares Fall 10%
China NT Pharma Expands Light Asset Operations
NT PHARMA: SUPPLEMENTAL ANNOUNCEMENT TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2023
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
The share consolidation of nt pharma (01011) has taken effect.
NT Pharma (01011) announced that the share merger has taken effect.
China NT Pharma Shareholders to Vote June 28 on Proposed Share Consolidation
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Tailin Pharmaceuticals plans to implement a share merger based on a “10 in 1” basis
Tailing Pharmaceutical (01011) announced that the board of directors recommended a share consolidation based on the basis of merging the issued and unissued shares with a face value of $0.0000,0008 per 10 shares into a consolidated share of $0.0000008 per share. On the date of this announcement, existing shares were traded on the Stock Exchange with 500 existing shares per lot. After the share merger comes into effect, it is proposed that each trading unit traded on the Stock Exchange be changed from 500 existing shares to 10,000 consolidated shares.
Tailing Pharmaceuticals (01011.HK) proposes to change the trading unit for each lot of “10 in 1” shares to 10,000 shares
Gelonghui, May 14, 丨 Tailing Pharmaceutical (01011.HK) announced that the board of directors proposed a “10 in 1” share merger. Stock consolidation is subject to shareholders' approval at a special shareholders' meeting before it can actually take place. After the share merger comes into effect, it is proposed to change the trading unit for each lot traded on the Stock Exchange from 500 existing shares to 10,000 consolidated shares.
Tailing Pharmaceutical (01011) plans to implement a share merger based on a “10 in 1” basis
Zhitong Finance App News, Tailing Pharmaceutical (01011) announced that the board of directors proposed a share consolidation based on the basis of merging issued and unissued shares with a face value of 0.00000008 US dollars per 10 shares into 1 consolidated share of 0.0000008 US dollars per share. On the date of this announcement, existing shares were traded on the Stock Exchange with 500 existing shares per lot. After the share merger comes into effect, it is proposed to change the trading unit for each lot traded on the Stock Exchange from 500 existing shares to 10,000 consolidated shares.
NT PHARMA: Annual Report 2023
No Data